Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients (LYRIC-HF)

A Randomized, Parallel Group, Placebo-controlled, Double-blind, Longitudinal, Single Treatment Center, Phase II Proof-of-concept Study to Evaluate the Efficacy and Safety of Lumacaftor in Stable Heart Failure Subjects With Reduced Ejection Fraction

Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes. Currently, there are no specific treatments for CI aside from the current standard of care therapy for HF, making this a high unmet medical need. Impaired cerebral autoregulation is a proposed mechanistic factor that leads to cerebral hypoperfusion, ischemic damage and the development for CI. Preclinical data indicates that restoring CFTR-protein expression normalizes cerebral microvascular function and cerebral blood flow (CBF) in models of HF. The purpose of this study is to investigate whether CFTR-targeting therapy enhances cerebral perfusion and cognitive function in heart failure patients using the CFTR-corrector Lumacaftor.

Study Overview

• Status: Recruiting
• Conditions: Heart Failure With Reduced Ejection Fraction
• Intervention / Treatment: Drug: Placebo; Drug: Lumacaftor 200 MG

Detailed Description

Recent preclinical research has identified wild-type cystic fibrosis transmembrane conductance regulator (CFTR) in cerebral artery smooth muscle cells as a key protein involved in the myogenic mechanism governing cerebrovascular reactivity and a potential therapeutic target. In experimental models of HF, CFTR-protein expression is downregulated, which is associated with increased vascular tone, reduced cerebral blood flow, increased neuronal damage and poorer scores on functional tests. Treatment with CFTR-correctors reverses the pathology and normalizes cerebral artery CFTR-expression, vascular tone, CBF, neuronal health and functional outcome. Lumacaftor is an existing small-molecule CFTR-corrector that increases the abundance of CFTR-protein at the cell membrane by augmenting its trafficking and stability. It is currently approved as part of a combination therapy (lumacaftor/ivacaftor) in cystic fibrosis patients with the CFTR F508del gene mutation.

The purpose of this trial is to build on the CFTR-stabilizing properties of lumacaftor in HF patients and determine whether clinical application of a CFTR-stabilizing treatment improves cerebral perfusion and cognitive performance. The study is a Phase II proof-of-concept, randomized, parallel group, placebo-controlled, double-blind, longitudinal, single treatment center trial of 60 stable adults with HFrEF (no hospitalization within 3 months) on optimal goal-directed medical therapy treated with lumacaftor vs. identical placebo. This will include participants who are New York Heart Association (NYHA) class II-III, with reduced cardiac output and an EF of <40%.

Following eligibility assessment and consent procedures, participants will undergo screening to measure baseline CBF using perfusion-weighted magnetic resonance imaging (MRI). Participants enrolled in the study will be allocated 1:1 to receive lumacaftor 200 mg q12 or identical placebo for 30 days. A follow-up cerebral MRI will assess the change from baseline at 1 month in global CBF as the primary outcome measure of the trial. In additional to safety metrics, a battery of neurocognitive assessments will be administered using the Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT), the Hospital Anxiety and Depression Scale (HADS) and the Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) to determine changes from baseline, at 1 month and 3 months in cognitive function, mental health, and quality of life as key secondary outcomes.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Qanatpharma Clinical Program Manager; Phone Number: 289-497-3801; Email: info@qanatpharma.com

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5B 1M8
      • Recruiting
      • St. Michael's Hospital
      • Principal Investigator: Kim Connelly, MD
      • Contact: Research Coordinator
    • Toronto, Ontario, Canada, M5G2N2
      • Not yet recruiting
      • University Health Network (UHN) Peter Munk Cardiac Centre
      • Contact: Research Coordinator
      • Principal Investigator: Filio Billia, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

Participants screened for enrolment must meet all of the following criteria to be eligible for study participation:

1. Provide written informed consent
2. Aged 18 years or older with stable heart failure NYHA class II-III, with reduced cardiac output and an EF of <40% on optimal goal directed medical therapy as per CCS Guidelines and the AHA/ACC/HFSA Guidelines for the Management of Heart Failure
3. No hospital admissions for inpatient care in 3 months prior to study
4. CBF at screening of ≤45 mL/100g/min
5. Able to comply with study procedures

6. Female participants must fulfill at least one of the following:

   1. Negative serum pregnancy (β-hCG) test at screening if participant is of childbearing potential (defined as having gone through menarche and not postmenopausal)
   2. Post-menopausal for a minimum of 1 year (defined as 12 consecutive months with no menses without an alternative medical cause) Be surgically sterile for a minimum of 6 months (achieved through partial/total hysterectomy, bilateral oophorectomy, or bilateral salpingectomy; note that tubal ligation is not considered a method of permanent sterilization)
7. Agree to avoid pregnancy and be willing to use medically acceptable methods of contraception for the duration of study and for 1 month after the last dose of the IMP (for females) and for 3 months after the last dose (for males)

Exclusion criteria

Participants screened for enrolment, meeting any of the following criteria are not eligible for study participation:

1. Participants with symptomatic HF who have non-MRI compatible cardiac implantable electronic devices (CIEDs), such as a cardiac defibrillator or pacemaker, or in whom this is required within 3 months of the study
2. Those requiring coronary revascularisation in 6 months following the study
3. Participants with cystic fibrosis (CF) or any other condition that may require use of CFTR modulating agents
4. Participants using antiallergics (e.g., montelukast), antibiotics (e.g., clarithromycin), anticoagulants (e.g., warfarin), anticonvulsants (e.g., carbamazepine), antidepressants (e.g., citalopram), antifungals (e.g., fluconazole), anti-mycobacterials (e.g., rifabutin), barbituates, benzodiazepines (e.g., midazolam), immunosuppressants (e.g., cyclosporine), proton pump inhibitors (e.g., esomeprazole) within 30 days of trial start
5. A history of or known seropositivity for human immunodeficiency virus (HIV) and active hepatitis B and/or C infection
6. Participants with moderate or severe hepatic disease (such as cirrhosis), or impaired liver function tests defined as serum ALT and/or AST >3 x the upper limit of normal (ULN) or total bilirubin >2 x ULN
7. Resting heart rate of >100 bpm
8. Symptomatic blood pressure <90 mmHg systolic
9. Any major deviation in clinical lab values and/or electrocardiograms deemed clinically significant at baseline that in the opinion of the investigator would compromise the outcome of the trial as it relates to the active therapy
10. Any clinically significant abnormalities in physical examination, neurological examination, vital signs, safety laboratory tests, and/or electrocardiograms that may impact the safety of the participant, in the opinion of the investigator
11. Any suicidal behaviour in the past 2 years (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour), or any suicidal ideation (type 4 or 5) in the last 6 months (i.e., active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent), as defined by the C-SSRS
12. Participants currently experiencing any clinically significant or unstable medical condition that in the opinion of the investigator might limit their ability to complete the study, or to comply with the requirements of the protocol, including dermatologic disease, haematological disease, pulmonary disease, kidney disease, hepatic disease, gastrointestinal disease, genitourinary disease, endocrine disease, neurological disease, and psychiatric disease
13. Participants with severe chronic obstructive pulmonary disease (COPD), or demonstrating a significant degree of pulmonary obstruction with a forced expiratory volume in the first second (FEV1) or forced vital capacity (FVC) that is <70% of the predicted normal value, or FEV/FVC ratio that is <65%
14. Females having used implanted, injected, intravaginal, or intrauterine hormonal contraceptive within 6 months prior to first study drug administration.
15. Females taking oral or transdermal hormonal contraceptives within 30 days prior to first study drug administration
16. Female participants who are currently breastfeeding or planning to breastfeed
17. Any malignancy not considered cured (except basal cell carcinoma of the skin). A participant is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening
18. Unstable coronary syndromes
19. Moderate or severe valvular disease
20. Body mass index >40 kg/m2
21. Estimated glomerular filtration rate (eGFR) of <30 ml/m2
22. Participants with a ferro-magnetic aneurysm clip or vascular clamp that is non-MRI compatible
23. Claustrophobia or inability to undergo MRI without sedation
24. Any other recognized CMRI contraindication as per local guidelines
25. Participants that have participated in a clinical study during the 3 months prior to screening, or that plan to participate in another clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lumacaftor; Participants receive 1 tablet of Lumacaftor 200 mg twice daily for 30 days.	Drug: Lumacaftor 200 MG; Lumacaftor 200 mg q12
Placebo Comparator: Placebo; Participants receive 1 tablet of Lumacaftor placebo tablet twice daily for 30 days.	Drug: Placebo; Identical placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy of lumacaftor treatment in increasing cerebral blood flow versus placebo in HFrEF patients.	Change from baseline in global cerebral blood flow at 1 month using treatment or placebo as assessed by perfusion weighted MRI.	Baseline and 1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of treatment-emergent adverse events as assessed by MedDRA.	Number of treatment-emergent AEs by severity and treatment received. This will capture participants who received at least one dose of treatment.	Baseline up to Day 90
Number of participants with clinically significant changes from baseline in physical examinations findings at 1 week, 1 month and 3 months.		Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in vital signs at 1 week, 1 month and 3 months.		Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in electrocardiograms (ECGs) at 1 week, 1 month and 3 months.		Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in laboratory test results at 1 week, 1 month and 3 months.		Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) at 1 week, 1 month and 3 months.	The C-SSRS is a questionnaire that captures severity and intensity of suicidal ideation and the number of suicidal behavioural attempts.	Baseline, 1 week, 1 month and 3 months
Changes from baseline in Montreal Cognitive Assessment (MoCA) scores at 1 month and 3 months.	MoCA is a screening tool for global cognitive function over several domains (memory, attention, language, visuospatial skills, and executive function). Scoring is 0-30-points, with higher scores indicating better global cognition function.	Baseline, 1 month and 3 months
Changes from baseline in the 36-Item Short Form Health Survey (SF-36) scores at 1 month and 3 months.	The SF-36 is a self-report, general measure of health status and quality of life, assessing eight domains (physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions). Scoring is 0-100 points for each domain, with higher scores indicating a more favourable health state.	Baseline, 1 month and 3 months
Changes from baseline in the Hospital Anxiety and Depression Scale (HADS) scores at 1 month and 3 months.	HADS is a self-report, 14-item measure to screen for depression and anxiety disorders among non-psychiatric, medically ill, outpatient populations. Scoring is 7 points for each domain of depression and anxiety, with scores of less than 7 for non-cases, 8-10 for mild cases, 11-14 for moderate cases and 15-21 for severe cases.	Baseline, 1 month and 3 months
Changes from baseline in the Trail-Making-Test (TMT) scores at 1 month and 3 months.	The TMT is an attention and task-switching, two-part test to measure executive and psychomotor function by connecting a series of dots accurately. Scoring is based on time to completion, with a score of more than 70-78 seconds deficient for TMT-A and a score of more than 180-273 seconds deficient for TMT-B.	Baseline, 1 month and 3 months

Collaborators and Investigators

• Sponsor: Qanatpharma AG
• Collaborators: Qanatpharma Canada LTD
• Investigators: Principal Investigator: Kim Connelly, Unity Health Toronto

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: May 5, 2025
• First Submitted That Met QC Criteria: July 5, 2026
• First Posted (Actual): July 10, 2026

Study Record Updates

• Last Update Posted (Actual): July 10, 2026
• Last Update Submitted That Met QC Criteria: July 5, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Cognitive Impairment; CFTR; Microvascular; Heart Failure with Reduced Ejection Fraction; Cerebral Blood Flow
• Additional Relevant MeSH Terms: Mental Disorders; Neurocognitive Disorders; Cognition Disorders; Cognitive Dysfunction; lumacaftor
• Other Study ID Numbers: QP586-A01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qanatpharma will provide access upon request to individual de-identified participant data reported in the publication beginning 12 months after publication and for up to 36 months following article publication. Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement. Contact information will be provided at the time of article publication.
• IPD Sharing Time Frame: 12 months after article publication and for up to 36 months following article publication.
• IPD Sharing Access Criteria: Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No